Nanotherapy in Joints: Increasing Endogenous Hyaluronan Production by Delivering Hyaluronan Synthase 2
- PMID: 31549776
- DOI: 10.1002/adma.201904535
Nanotherapy in Joints: Increasing Endogenous Hyaluronan Production by Delivering Hyaluronan Synthase 2
Abstract
Osteoarthritis (OA) is a common joint degenerative disease that causes pain, joint damage, and dysfunction. External hyaluronic acid (HA) supplement is a common method for the management of osteoarthritis which requires multi-injections. It is demonstrated that biodegradable mesoporous silica nanoparticles successfully deliver an enzyme, hyaluronan synthase type 2 (HAS2), into synoviocytes from the temporomandibular joint (TMJ) and generate endogenous HA with high molecular weights. In a rat TMJ osteoarthritis inflammation model, this strategy promotes endogenous HA production and inhibits the synovial inflammation of OA for more than 3 weeks with one-shot administration. Such nanotherapy also helps repairing the bone defects in a rat OA bone defect model.
Keywords: drug carriers; hyaluronic acid; nanoparticles; osteoarthritis; protein delivery.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
References
-
- H. A. Wieland, M. Michaelis, B. J. Kirschbaum, K. A. Rudolphi, Nat. Rev. Drug Discovery 2005, 4, 331.
-
- J. R. Bush, F. Beier, Nat. Med. 2013, 19, 667.
-
- M. C. Hochberg, R. D. Altman, K. T. April, M. Benkhalti, G. Guyatt, J. McGowan, T. Towheed, V. Welch, G. Wells, P. Tugwell, Arthritis Care Res. 2012, 64, 465.
-
- D. J. Hunter, N. Engl. J. Med. 2015, 372, 1040.
-
- S. Gladstone, N. Engl. J. Med. 2015, 372, 2569.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical